» Articles » PMID: 33264280

Drug2ways: Reasoning over Causal Paths in Biological Networks for Drug Discovery

Overview
Specialty Biology
Date 2020 Dec 2
PMID 33264280
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Elucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological state, leading the way for enhanced disease characterization and the design of advanced therapies. Network-based approaches, in particular, are highly suited for these purposes as they hold the capacity to identify the molecular mechanisms underlying disease. Here, we present drug2ways, a novel methodology that leverages multimodal causal networks for predicting drug candidates. Drug2ways implements an efficient algorithm which reasons over causal paths in large-scale biological networks to propose drug candidates for a given disease. We validate our approach using clinical trial information and demonstrate how drug2ways can be used for multiple applications to identify: i) single-target drug candidates, ii) candidates with polypharmacological properties that can optimize multiple targets, and iii) candidates for combination therapy. Finally, we make drug2ways available to the scientific community as a Python package that enables conducting these applications on multiple standard network formats.

Citing Articles

Comprehensive applications of the artificial intelligence technology in new drug research and development.

Chen H, Lu D, Xiao Z, Li S, Zhang W, Luan X Health Inf Sci Syst. 2024; 12(1):41.

PMID: 39130617 PMC: 11310389. DOI: 10.1007/s13755-024-00300-y.


A comparative benchmarking and evaluation framework for heterogeneous network-based drug repositioning methods.

Li Y, Yang Y, Tong Z, Wang Y, Mi Q, Bai M Brief Bioinform. 2024; 25(3).

PMID: 38647153 PMC: 11033846. DOI: 10.1093/bib/bbae172.


Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing.

Garana B, Joly J, Delfarah A, Hong H, Graham N BMC Bioinformatics. 2023; 24(1):215.

PMID: 37226094 PMC: 10207828. DOI: 10.1186/s12859-023-05343-8.


Ensembles of knowledge graph embedding models improve predictions for drug discovery.

Rivas-Barragan D, Domingo-Fernandez D, Gadiya Y, Healey D Brief Bioinform. 2022; 23(6).

PMID: 36384050 PMC: 9677479. DOI: 10.1093/bib/bbac481.


Machine Learning for Causal Inference in Biological Networks: Perspectives of This Challenge.

Lecca P Front Bioinform. 2022; 1:746712.

PMID: 36303798 PMC: 9581010. DOI: 10.3389/fbinf.2021.746712.


References
1.
Yeh S, Yeh H, Soo V . A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer. J Clin Bioinforma. 2012; 2(1):1. PMC: 3285036. DOI: 10.1186/2043-9113-2-1. View

2.
Misselbeck K, Parolo S, Lorenzini F, Savoca V, Leonardelli L, Bora P . A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome. Nat Commun. 2019; 10(1):5215. PMC: 6861239. DOI: 10.1038/s41467-019-13208-z. View

3.
Matsunaga S, Kishi T, Iwata N . Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014; 18(5). PMC: 4376554. DOI: 10.1093/ijnp/pyu115. View

4.
Guney E, Menche J, Vidal M, Barabasi A . Network-based in silico drug efficacy screening. Nat Commun. 2016; 7:10331. PMC: 4740350. DOI: 10.1038/ncomms10331. View

5.
Barabasi A, Gulbahce N, Loscalzo J . Network medicine: a network-based approach to human disease. Nat Rev Genet. 2010; 12(1):56-68. PMC: 3140052. DOI: 10.1038/nrg2918. View